Hyperparathyroidism
📧 Sign up to get email alerts when something new happens for Hyperparathyroidism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-06-08Clinical Trial Update: Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level [Phase 4]
A Phase 4 trial evaluating cinacalcet in peritoneal dialysis patients with secondary hyperparathyroidism to lower iPTH levels has completed.
-
CLINICAL_TRIALS research · 2012-05-30Clinical Trial Update: The Effect of Parathyroidectomy on Renal Function, Endothelial Function, and Blood Pressure
This clinical trial assesses the impact of parathyroidectomy on renal function, endothelial function, and blood pressure in individuals with…
-
CLINICAL_TRIALS trial_result · 2012-03-12Clinical Trial Update: Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism
A completed follow-up trial in end-stage renal disease patients treated with Zemplar (paricalcitol) to prevent and treat secondary hyperpara…
-
CLINICAL_TRIALS trial_result · 2012-02-07Clinical Trial Update: Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease [NA]
Completed clinical trial evaluating whether vitamin D can prevent secondary hyperparathyroidism in patients with stage II/III chronic kidney…
-
CLINICAL_TRIALS research · 2011-11-24Clinical Trial Update: Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) [Phase 2, Phase 3]
Clinical trial update on pediatric cinacalcet for secondary hyperparathyroidism due to chronic kidney disease (Phase 2/3). The current statu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2011-11-16Clinical Trial Update: The Effects of Alendronate After Cure of Primary Hyperparathyroidism [Phase 4]
A Phase 4 clinical trial evaluating the effects of alendronate after cure of primary hyperparathyroidism has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2011-10-31Clinical Trial Update: Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose [Phase 4]
Phase 4 trial evaluating the effectiveness and safety of intravenous Zemplar (paricalcitol) in patients on hemodialysis with secondary hyper…
-
CLINICAL_TRIALS trial_result · 2011-10-25Clinical Trial Update: Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis [Phase 4]
Phase 4 trial evaluating 6 months of paricalcitol injections or oral therapy for secondary hyperparathyroidism in dialysis patients; results…
-
CLINICAL_TRIALS trial_result · 2011-09-12Clinical Trial Update: Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis
A clinical trial evaluating intravenous paricalcitol (Zemplar IV) in patients with end-stage chronic kidney disease on haemodialysis for man…
-
FDA approval · 2011-08-01FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)
The FDA approves a supplemental application for Sensipar (cinacalcet hydrochloride) submitted by Amgen Inc.
-
CLINICAL_TRIALS trial_result · 2011-07-22Clinical Trial Update: Quality of Life in Patients Undergoing Parathyroidectomy
A completed clinical trial evaluating quality of life after parathyroidectomy in patients with hyperparathyroidism.
-
CLINICAL_TRIALS trial_result · 2011-07-13Clinical Trial Update: A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) [Phase 4]
Phase 4 trial evaluating cinacalcet's ability to help end-stage renal disease patients meet K/DOQI targets for secondary hyperparathyroidism…
-
CLINICAL_TRIALS trial_result · 2011-06-17Clinical Trial Update: Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism [Phase 2]
Phase 2 trial comparing paricalcitol to maxacalcitol in chronic kidney disease patients with secondary hyperparathyroidism has completed and…
-
CLINICAL_TRIALS trial_result · 2011-04-27Clinical Trial Update: Evaluation of MRI and SPECT Fusion Software to Localize Parathyroid Adenomas
A terminated clinical trial evaluated MRI and SPECT fusion software to localize parathyroid adenomas. The study was sponsored by State Unive…
-
CLINICAL_TRIALS trial_result · 2011-04-19Clinical Trial Update: Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) [Phase 2]
Phase 2 long-term safety study of paricalcitol injections in chronic kidney disease patients on hemodialysis has completed and results were …
-
FDA label_change · 2011-04-06FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for ZEMPLAR (paricalcitol) from AbbVie, updating its labeling.
-
FDA approval · 2011-04-06FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Zemplar (paricalcitol) filed by AbbVie Inc., approving an update to the product labeling.
-
CLINICAL_TRIALS other · 2011-04-04Clinical Trial Update: Treatment of Secondary Hyperparathyroidism in the Uremic Patient [NA]
A clinical trial (NCT00469599) examining treatment of secondary hyperparathyroidism in uremic patients with chronic kidney disease has been …
-
CLINICAL_TRIALS trial_result · 2011-03-24Clinical Trial Update: Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients [Phase 4]
Phase 4 clinical trial update examining vitamin D deficiency in patients with chronic kidney disease and secondary hyperparathyroidism.
-
CLINICAL_TRIALS trial_result · 2011-03-01Clinical Trial Update: Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients [Phase 2]
Phase 2 trial in chronic kidney disease patients with secondary hyperparathyroidism completed; results were posted in 2011.
-
FDA approval · 2011-02-01FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Zemplar (paricalcitol) submitted by AbbVie.
-
CLINICAL_TRIALS trial_result · 2011-01-19Clinical Trial Update: Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis [Phase 3]
Phase 3 trial update indicating completion of a study evaluating Zemplar Capsule (paricalcitol) for reducing serum intact parathyroid hormon…
-
CLINICAL_TRIALS trial_result · 2010-10-27Clinical Trial Update: ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis [Phase 4]
A Phase 4 study evaluated whether cinacalcet plus low-dose vitamin D affects vascular calcification in adults with chronic kidney disease on…
-
CLINICAL_TRIALS research · 2010-10-22Clinical Trial Update: The Novel Approach of Minimally Invasive Parathyroid Surgery Requires Precise Identification and Localization of the Lesion Prior to Exploration
A clinical-trial update describing a minimally invasive parathyroid surgical approach that requires precise identification and localization …
-
CLINICAL_TRIALS research · 2010-10-15Clinical Trial Update: Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma
An update on a clinical trial evaluating C11-choline PET/CT for localization of parathyroid adenomas. The study targets hyperparathyroidism.